Safety Communications > UPDATE: Potential Eye Damage from Alcon CyPass Micro-Stent Used to Treat Open-Angle Glaucoma: FDA Safety Communication

Safety Communications > UPDATE: Potential Eye Damage from Alcon CyPass Micro-Stent Used to Treat Open-Angle Glaucoma: FDA Safety Communication



UPDATE: Potential Eye Damage from Alcon CyPass Micro-Stent Used to Treat Open-Angle Glaucoma: FDA Safety Communication



The FDA is issuing this communication to provide additional information regarding corneal endothelial cell loss in patients who have received the Alcon CyPass Micro-Stent. This communication also contains updated recommendations to clinicians who care for patients implanted with the device as well as information related to its recall. Continue reading.